Clinical trials: insulin glargine
Diabetes Mellitus, Type 2
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: Change in participants' overall blood sugar control The rate of night time low…
- Trial name
- IMAGINE 5 (NCT01582451)
- Testing
- LY2605541, Insulin glargine
- Where
- 61 sites in United States, Czechia and 7 more
- Volunteers
- 466 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus.
- Trial name
- GLANS (NCT00539448)
- Testing
- insulin glargine, insulin glulisine
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus
To compare the efficacy (in terms of metabolic control evaluated through HbA1c levels) of treatment with insulin glargine as basal insulin and insulin analogue (insulin lispro) as mealtime insulin with a regimen of insulin NPH as…
- Trial name
- NCT00537251
- Testing
- Insulin glargine
- Volunteers
- 80 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Obesity
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes.
- Trial name
- NCT05514535
- Testing
- Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
- Where
- 239 sites in United States, Czechia and 10 more
- Volunteers
- 573 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT).
- Trial name
- NCT07307235
- Testing
- iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
- Where
- 24 sites in China
- Volunteers
- 1,316 people
- Sponsor
- Shanghai Zhongshan Hospital
Type 2 Diabetes
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin…
- Trial name
- NCT05834868
- Testing
- THDB0206 Injection, Insulin Lispro Injection
- Where
- China
- Volunteers
- 1,040 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is: To compare blood glucose (blood sugar) control on LY2605541 with insulin glargine after 26 weeks of treatment.
- Trial name
- IMAGINE 4 (NCT01468987)
- Testing
- LY2605541, Insulin Glargine, Insulin Lispro
- Where
- 156 sites in United States, Australia and 23 more
- Volunteers
- 1,369 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both…
- Trial name
- BOOST™ (NCT01045707)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 92 sites in United States, Austria and 7 more
- Volunteers
- 530 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes…
- Trial name
- NCT02688933
- Testing
- HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy
- Where
- 100 sites in United States, Puerto Rico
- Volunteers
- 638 people
- Sponsor
- Sanofi
Type 2 Diabetes
The Impact of Food on Blood Sugar in People With Type 2 Diabetes
This study will record the impact of food on blood glucose levels using continuous glucose monitoring (CGM). The investigators think the impact will improve as medication doses are adjusted.
- Trial name
- REACT2 (NCT01237314)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- HealthPartners Institute
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-T1D (NCT03214367)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 172 sites in United States, Argentina and 18 more
- Volunteers
- 1,392 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Pharmacist Intervention for Glycemic Control in The Community
Background: Approximately 1.9 million Canadians are living with diabetes and this is estimated to increase by 75% over the next few decades.
- Trial name
- RxING (NCT01335763)
- Testing
- Insulin glargine
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Alberta
Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function
Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy
This randomized controlled prospective study aims to evaluate the efficacy of intensive insulin therapy for long term glycemic control and improvement or preservation of beta cell function in newly diagnosed type 2 diabetes…
- Conditions
- Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity
- Trial name
- KIIT (NCT00474838)
- Testing
- intensive insulin group, Oral AntiDiabetic Drug (glimepiride and metformin)
- Where
- 8 sites in South Korea
- Volunteers
- 112 people
- Sponsor
- Kyunghee University Medical Center
Hyperglycaemic Crisis in Diabetes Mellitus, Diabetic Ketoacidosis
Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care
The safety and efficacy of basal insulin during intravenous insulin infusion for hyperglycemic crisis patients under critical care is still unknown.
- Conditions
- Hyperglycaemic Crisis in Diabetes Mellitus, Diabetic Ketoacidosis, Hyperglycaemic Hyperosmolar Nonketotic Syndrome
- Trial name
- NCT05155917
- Testing
- Insulin Glargine 300 UNT/ML [Toujeo]
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- Changhua Christian Hospital
Diabetes Mellitus
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs).
- Trial name
- NCT00348374
- Testing
- Insulin Lispro, Exubera
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 191 people
- Sponsor
- Pfizer
Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects.
- Conditions
- Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes
- Trial name
- NCT07117240
- Testing
- lixisenatide + glargine, Intensive insulin therapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Type 2 Diabetes
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
- Trial name
- NCT06716424
- Testing
- iGlarLixi (insulin glargine/lixisenatide)
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Sanofi
Diabetes
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in terms of diabetes control…
- Trial name
- NCT01203774
- Testing
- Glargine insulin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Colorado, Denver
Glucose, Blood
Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients
Insulin infusions are commonly used in hospitalized diabetics to control blood sugar, and they are effective. However, insulin infusions require the use of limited resources.
- Trial name
- IICE (NCT00645827)
- Testing
- IICE Dosing, Healthcare Provider dosing
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM.
- Trial name
- IMPERIUM (NCT02072096)
- Testing
- Glimepiride, Metformin, Pioglitazone
- Where
- 34 sites in United States, Austria and 3 more
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company